X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4285) 4285
Publication (554) 554
Newsletter (480) 480
Newspaper Article (104) 104
Book Review (59) 59
Magazine Article (28) 28
Book Chapter (19) 19
Trade Publication Article (5) 5
Conference Proceeding (2) 2
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
tenofovir (3201) 3201
humans (2661) 2661
index medicus (2311) 2311
female (1457) 1457
tenofovir disoproxil fumarate (1452) 1452
male (1410) 1410
hiv (1386) 1386
infectious diseases (1345) 1345
hiv infections - drug therapy (1236) 1236
adult (1174) 1174
adenine - analogs & derivatives (1158) 1158
hepatitis b (958) 958
middle aged (897) 897
emtricitabine (853) 853
pharmacology & pharmacy (808) 808
drug therapy (780) 780
anti-hiv agents - therapeutic use (775) 775
human immunodeficiency virus--hiv (759) 759
immunology (741) 741
lamivudine (686) 686
hiv infection (653) 653
adenine - therapeutic use (645) 645
health aspects (635) 635
antiretroviral therapy (634) 634
research (623) 623
antiviral agents (617) 617
treatment outcome (590) 590
virology (567) 567
antiviral agents - therapeutic use (563) 563
anti-hiv agents - administration & dosage (553) 553
organophosphonates - therapeutic use (553) 553
hepatitis b, chronic - drug therapy (547) 547
disoproxil fumarate (544) 544
gastroenterology & hepatology (543) 543
infection (519) 519
care and treatment (512) 512
therapy (503) 503
anti-hiv agents - adverse effects (497) 497
hepatitis b virus (468) 468
prevention (457) 457
risk factors (448) 448
hiv infections - prevention & control (445) 445
hepatitis (431) 431
antiretroviral drugs (426) 426
safety (420) 420
drug therapy, combination (414) 414
dosage and administration (408) 408
deoxycytidine - analogs & derivatives (407) 407
microbiology (405) 405
adenine - adverse effects (395) 395
virus diseases (394) 394
adenine - administration & dosage (390) 390
viral load (375) 375
analysis (372) 372
highly active antiretroviral therapy (372) 372
aids (364) 364
aids/hiv (363) 363
young adult (360) 360
entecavir (352) 352
organophosphonates - adverse effects (343) 343
organophosphonates - administration & dosage (341) 341
infections (338) 338
medical research (337) 337
acquired immune deficiency syndrome--aids (335) 335
drug combinations (334) 334
double-blind (329) 329
human-immunodeficiency-virus (329) 329
tenofovir - therapeutic use (328) 328
hiv infections - virology (326) 326
pharmacokinetics (326) 326
clinical trials (323) 323
hiv-1 - drug effects (318) 318
adefovir dipivoxil (316) 316
efficacy (301) 301
patients (299) 299
hiv infections - complications (298) 298
efavirenz (291) 291
medicine (289) 289
adolescent (285) 285
drug resistance, viral (277) 277
biological products industry (267) 267
medicine, experimental (265) 265
drug resistance (263) 263
human immunodeficiency virus (258) 258
animals (257) 257
pregnancy (253) 253
research article (248) 248
article (244) 244
hiv-infected patients (242) 242
lamivudine - therapeutic use (240) 240
risk (240) 240
chronic hepatitis b (236) 236
viruses (236) 236
deoxycytidine - therapeutic use (230) 230
hepatitis b virus - drug effects (230) 230
hiv patients (228) 228
medicine & public health (228) 228
aged (226) 226
antiretroviral agents (226) 226
hiv-1 (226) 226
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4756) 4756
Korean (66) 66
French (30) 30
German (20) 20
Spanish (19) 19
Chinese (6) 6
Japanese (3) 3
Turkish (3) 3
Czech (2) 2
Polish (2) 2
Arabic (1) 1
Indonesian (1) 1
Italian (1) 1
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2008, Volume 359, Issue 23, pp. 2442 - 2455
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 02/2019, Volume 844, pp. 139 - 144
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9865, pp. 468 - 475
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 140, Issue 1, pp. 132 - 143
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 4, pp. 980 - 988.e1
Background & Aims Tenofovir disoproxil fumarate (TDF) is active against lamivudine-resistant hepatitis B virus (HBV) infection, but data to support its... 
Gastroenterology and Hepatology | HBV DNA | Hepatitis B e Antigen | Renal Function | Viral Suppression | GENOTYPIC RESISTANCE | ENTECAVIR | VIRUS | MANAGEMENT | BONE-MINERAL DENSITY | COMBINATION THERAPY | TURNOVER MARKERS | NUCLEOTIDE ANALOGS | NAIVE PATIENTS | ADEFOVIR DIPIVOXIL | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Humans | Middle Aged | Male | Hepatitis B, Chronic - diagnosis | North America | Viral Load | Lamivudine - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Time Factors | Adenine - therapeutic use | Lamivudine - therapeutic use | Adult | Deoxycytidine - adverse effects | Female | Hepatitis B virus - immunology | Emtricitabine | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Europe | Organophosphonates - adverse effects | Genotype | Treatment Outcome | Biomarkers - blood | DNA, Viral - blood | New Zealand | Hepatitis B virus - drug effects | Drug Resistance, Viral - genetics | Hepatitis B, Chronic - drug therapy | Antiviral Agents - adverse effects | Hepatitis B virus - genetics | Hepatitis B e Antigens - blood | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Care and treatment | Lamivudine | Comparative analysis | Health aspects | Hepatitis B
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 08/2015, Volume 69, Issue 4, pp. 439 - 445
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article